User Evaluation of a Home-collection Kit for People With Diabetes

Sponsor
University Hospitals of North Midlands NHS Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06038669
Collaborator
(none)
50
1
15
3.3

Study Details

Study Description

Brief Summary

Type 1 and Type 2 are the most common types of diabetes mellitus. Although the cause of Type 1 is different to Type 2, they can both lead to high blood glucose levels as the patient is unable to store and use sugar. The disease is an epidemic of the 21st century which is increasing, having a current prevalence of approximately 8%.

Poor disease control is associated with a range of long-term health conditions which have a severe impact upon quality of life and are responsible for the increased morbidity and mortality associated with the disease.

Healthcare professionals use HbA1c as the main marker to monitor diabetic control. Patients with diabetes have regular review appointments to monitor their overall health and discuss their HbA1c target and results. The purpose of monitoring patients with diabetes is to improve patient outcomes. It is known that poor control is associated with poor clinical outcomes and also that reduced monitoring is linked to suboptimal diabetic control. Therefore, aiming for the correct monitoring frequency helps towards achieving the best control which can lead to the most favourable clinical outcomes. The inconvenience of attending for a blood test and follow-up appointment is a major factor affecting patient adherence to monitoring, locally approximately 50% of patients with diabetes have their HbA1c level measured either too soon or too late.

To address this issue and improve access to monitoring at the correct time interval we aim to produce a HbA1c home testing kit which can be posted back to the laboratory at the convenience of the patient. The kit will be developed based on feedback from patients with diabetes and will use a dried blood spot sample to produce HbA1c results comparable to the whole blood standard method.

Condition or Disease Intervention/Treatment Phase
  • Device: Dried blood spot device
  • Other: Healthcare professional interviews

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
User Evaluation of a Home-collection Kit for People With Diabetes
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Nov 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
People with diabetes

Patients who have diabetes will be asked to use a home collection kit to collect a dried blood spot sample which will be compared to the HbA1C result.

Device: Dried blood spot device
Patients will be asked to provide a dried blood spot sample

Health care professionals

Health care professionals who work with diabetic patients will be interviewed and asked about diabetes monitoring in the healthcare setting, comments on current laboratory service, patient engagement, comments on service improvement

Other: Healthcare professional interviews
Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring

Outcome Measures

Primary Outcome Measures

  1. DBS kit assay performance [1 year, 3 months]

    For the DBS-based home collection kit used by patients to be 'fit for purpose', it must achieve the following: Assay performance - correlation and bias. Correlation coefficient (r2 value) from linear regression plot should be >0.95 with a bias of less than 5%.

Secondary Outcome Measures

  1. Participant questionnaires theme analysis [1 year, 3 months]

    Completed participant questionnaires will be collated and analysed for themes. We aim to determine whether participants deem the home-collection kit to be acceptable. The information gained will be used to design a full study.

  2. Interviews [1 year, 3 months]

    The health care professional interview transcripts will be recorded and analysed. The emerging themes will be taken into consideration when designing the full study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Diagnosis of Type I or Type II diabetes

  • Aged 18 years or over

  • Venous blood sample for HbA1c collected within the two weeks prior to the clinic appointment

  • Ability to provide fully informed consent

Exclusion Criteria:
  • Non-English speaking where translation of the study documents and procedures could limit fully informed consent

  • Severe visual impairment which would leave the participant unable to complete the study procedures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals of North Midlands NHS Trust Stoke-on-Trent United Kingdom

Sponsors and Collaborators

  • University Hospitals of North Midlands NHS Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospitals of North Midlands NHS Trust
ClinicalTrials.gov Identifier:
NCT06038669
Other Study ID Numbers:
  • 3242
First Posted:
Sep 15, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023